Rheumatoid Arthritis

July 25th 2024

Patients without insurance may not be able to afford the biosimilar adalimumab-adbm, even if it is available at a more affordable price than its reference product.

July 15th 2024

After failure with methotrexate, treatment with leflunomide is typically recommended, but treatment with biosimilars could have greater quality-adjusted life years.

June 20th 2024

Investigators compared the reference products of adalimumab (Humira; AbbVie) and etanercept (Enbrel; Amgen) with biosimilar products.

March 7th 2024

Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.